THE IMPACT OF SUPERIMPOSED METABOLICDYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) ON CLINICAL AND PATIENT-REPORTED OUTCOMES (PROS) PROFILE OF PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND C (CHC)
Recommended Citation
Younossi Z, Buti M, Papatheodoridis G, Yilmaz Y, Yu M, El-Kassas M, Alswat K, Castellanos Fernandez MI, Eguchi Y, Duseja A, Keklikkiran C, Hamid S, Chan WK, Gordon S, Roberts S, George J, Singal A, Ahmed A, Lam B, Nader F, Henry L, Stepanova M, Alqahtani S. THE IMPACT OF SUPERIMPOSED METABOLICDYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) ON CLINICAL AND PATIENT-REPORTED OUTCOMES (PROS) PROFILE OF PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND C (CHC). Hepatology 2024; 80:S200-S201.
Document Type
Conference Proceeding
Publication Date
10-9-2024
Publication Title
Hepatology
Abstract
Background: CHB, CHC and MASLD are common causes of liver disease. We aimed to assess clinical and PRO profiles of patients with CHB and CHC with and without superimposed MASLD using the Global Liver Registry™. Methods: Clinical and PRO (FACIT-F, CLDQ, WPAI) data were analyzed from CHB and CHC patients from GLR. Superimposed MASLD was defined as Hepatic Steatosis Index (HSI) ≥ 36 and presence of > 1 cardio-metabolic risk factor (overweight, type 2 diabetes, hypertension, hyperlipidemia). Results: We included 4,649 subjects: 2,063 CHB (48 ± 13 years, 57% male, 11% advanced fibrosis) and 2,586 CHC subjects (56 ±14 years, 47% male, 18% advanced fibrosis). Among CHB, 49% had superimposed MASLD. CHB patients with and without MASLD were similar in age, sex, and had similar rates of advanced fibrosis (defined as FIB-4 ≥ 2.67 or liver stiffness ≥ 12 kPa), biopsy-proven cirrhosis, and non-cardio-metabolic comorbidities (all p > 0.05). Despite this, CHB patients with MASLD had significantly lower PRO scores in the domains of Physical Well-Being and Fatigue of FACITF, and all six domains of CLDQ (all p <0.01); the greatest impairment was observed in the Fatigue domain of CLDQ (-6% of the score range size). In multivariate analysis, the presence of superimposed MASLD in CHB was independently associated with lower scores in these domains after adjustment for confounders (p <0.05). Among CHC, 47% had superimposed MASLD. CHC patients with MASLD were younger and more commonly female (p <0.01). However, they had similar rates of advanced fibrosis, biopsy-proven cirrhosis, and non-cardio-metabolic comorbidities (all p > 0.05). CHC patients with MASLD had lower PRO scores in Physical Well-Being domain of FACIT-F and all four domains of CLDQ-HCV (all p< 0.01); the greatest impairment was observed in Systemic Symptoms and Worry domains of CLDQ-HCV (-6% of the score range size). In multivariate analysis, presence of superimposed MASLD in CHC was independently associated with lower scores in CLDQHCV domains after adjustment for confounders (p< 0.05). In comparison to CHC+MASLD, CHB +MASLD were younger (48 vs. 54 years), more commonly male (58% vs. 39%) with lower rates of advanced fibrosis (10% vs. 18%) and select nonhepatic comorbidities, and had higher PRO scores in most domains (3/5 domains of FACIT-F, work productivity and activity impairment by WPAI) (p <0.05). Conclusion: Almost half of the patients with CHC or CHB had superimposed MASLD. The clinical profile between those with viral hepatitis with or without MASLD is similar but those with superimposed MASLD reported a significant impairment in their patientreported outcomes.
Volume
80
First Page
S200
Last Page
S201
